1.
|
Phase: Phase IV Type: Natural history/Epidemiology Status: Enrolling by invitation Age: Postmenopausal Sponsor: Pharmaceutical / Industry Protocol IDs: A5991089, NCT01047358
|
|
2.
|
Phase: Phase IV Type: Natural history/Epidemiology Status: Closed Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: A5991091, NCT01121549
|
|
3.
|
Phase: Phase III, Phase II Type: Treatment Status: Closed Age: Postmenopausal Sponsor: NCI Protocol IDs: ACOSOG-Z1031, CALGB-ACOSOG-Z1031, SDC1, NCT00265759
|
|
4.
|
Phase: Phase III Type: Treatment Status: Completed Age: Postmenopausal Sponsor: Other Protocol IDs: EORTC-10951, PHARMACIA-EORTC-10951, NCT00002777
|
|
5.
|
Phase: Phase III Type: Treatment Status: Closed Age: Postmenopausal Sponsor: Protocol IDs: ICCG-96OEXE031-C1396-BIG9702, EORTC-10967, FRE-FNCLCC-PACS02/96OEXE031, EU-20013, EU-99002, ICCG-BIG-97/02, NCT00003418
|
|
6.
|
Phase: Phase III Type: Treatment Status: Closed Age: Any age Sponsor: Other Protocol IDs: CRC-TU-TEAM, EU-20149, ISRCTN75225940, NCT00032136
|
|
7.
|
Phase: Phase III Type: Treatment Status: Closed Age: Premenopausal Sponsor: NCI, Other Protocol IDs: CDR0000316456, IBCSG 24-02, BIG 2-02, CALGB-IBCSG 24-02, CAN-NCIC-IBCSG 24-02, NCCTG-IBCSG 24-02, NSABP-IBCSG 24-02, SWOG-IBCSG 24-02, NABCI-IBCSG 24-02, UCLA-0403024-01, EU-20334, EUDRACT-2004-000166-13, NCT00066690
|
|
8.
|
Phase: Phase III Type: Treatment Status: Closed Age: Premenopausal Sponsor: NCI, Other Protocol IDs: CDR0000316458, IBCSG-25-02, BIG-3-02, NABCI-IBCSG-25-02, EU-20347, EUDRACT-2004-000168-28, NCT00066703
|
|
9.
|
Phase: Phase III Type: Treatment Status: Closed Age: Premenopausal Sponsor: NCI, Other Protocol IDs: CDR0000318832, IBCSG-26-02, BIG-4-02, NABCI-IBCSG-26-02, EU-20401, 2005-002626-59, EUDRACT-2005-002626-59, NCT00066807
|
|
10.
|
Phase: Phase III Type: Treatment Status: Closed Age: Postmenopausal Sponsor: Pharmaceutical / Industry Protocol IDs: 9238IL/0048, EFECT, D6997C00048, NCT00065325
|
|
11.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Prevention Status: Closed Age: 35 and over Sponsor: Other Protocol IDs: MAP3, CAN-NCIC-MAP3, PFIZER-EXEAPO-0028-150, ExCel, CDR0000363802, NCT00083174
|
|
12.
|
Phase: Phase III Type: Treatment Status: Completed Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A5991048, NCT00143390
|
|
13.
|
Phase: Phase III Type: Treatment Status: Completed Age: 50 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 971-ONC-0028-081, A5991026, NCT00036270
|
|
14.
|
Phase: Phase III Type: Treatment Status: Closed Age: Any age Sponsor: Other Protocol IDs: CDR0000448616, ICR-CTSU-SOFEA, EU-20531, SSA-04Q200635, ISRCTN44195747, MREC-03677, EUDRACT-2004-000093-30, NCT00253422
|
|
15.
|
Phase: Phase III Type: Treatment Status: Closed Age: 30 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 96-OEXE-031, A5991012, NCT00038467
|
|
16.
|
Phase: Phase III Type: Treatment Status: Closed Age: Premenopausal Sponsor: Other Protocol IDs: ICORG-06-02, ICORG 06-02, IBCSG 24-02, SOFT, BIG 2-02, EUDRACT-2004-000166-13, EU-20916, NCT00917969
|
|
17.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001Y2301, 2008-008698-69, NCT00863655
|
|
18.
|
Phase: Phase III Type: Treatment Status: Completed Age: Postmenopausal Sponsor: Pharmaceutical / Industry Protocol IDs: 9238UK/0005, NCT00944918
|
|
19.
|
Phase: Phase III Type: Treatment Status: Completed Age: Postmenopausal Sponsor: NCI, Other Protocol IDs: NSABP B-33, CDR0000068640, ECOG-NSABP-B-33, NCT00016432
|
|
20.
|
Phase: Phase III Type: Treatment Status: Completed Age: Postmenopausal Sponsor: NCI, Other Protocol IDs: MA27, CAN-NCIC-MA27, NCCTG-MA27, CALGB-CAN-NCIC-MA27, ECOG-CAN-NCIC-MA27, SWOG-CAN-NCIC-MA27, IBCSG-30-04, EUDRACT-2005-001893-28, CDR0000316325, CAN-NCIC-MA27-COMPANION, NCIC-MA.27, NCT00066573
|
|
21.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: MCC-8539, 8539, NCT01149356
|
|
22.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: LCCC 2010-535, NCT01484041
|
|
23.
|
Phase: Phase II Type: Treatment Status: Closed Age: 25 to 90 Sponsor: Other Protocol IDs: YALE-HIC-7480, NCI-V95-0725
|
|
24.
|
Phase: Phase II Type: Treatment Status: Closed Age: postmenopausal Sponsor: Protocol IDs: YALE-HIC-7437, NCI-V95-0726
|
|
25.
|
Phase: Phase II Type: Prevention, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-99017, NCI-G99-1662, NCT00004247
|